Parkinnova Therapeutics, focuses on developing novel treatments for midbrain dopamine disorders like Parkinson’s disease. The company targets the PDE11a pathway to upregulate dopamine production. Parkinnova aims to bring innovative therapies to clinical trials, addressing significant unmet needs in neurodegenerative diseases. The company is committed to advancing neuroscience through cutting-edge research.